In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus ...

Bristol Myers Squibb partners with BioNTech in a $11.1B deal to develop BNT327, a promising cancer immunotherapy. Read more ...

Bristol Myers Squibb is partnering with BioNTech on a closely watched cancer drug, in a deal worth billions of dollars.